{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:38:40Z","timestamp":1762324720895,"version":"3.40.5"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1\u2010negative myeloproliferative neoplasms. The aim of this study was to evaluate the real\u2010life use of anagrelide in patients with ET followed over 25\u00a0years at the Haematological Institutes belonging to \u201cPh1\u2010negative Myeloproliferative Neoplasms Latium Group.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Eligibility criteria were diagnosis of ET and treatment with anagrelide. Data were collected through an ad hoc case report form.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and fifty patients received anagrelide for a median time of 7.4\u00a0years (0.1\u201023.2). Anagrelide was administered as first\u2010line therapy in 34.7% of patients, as second\u2010line in 52% and as third\u2010line in 13.3%: 85.4% responded to therapy. Sixty\u2010eight\/136 evaluable patients reported side effects: palpitations, peripheral vasodilation, anaemia, diarrhoea and gastric distress. Fourteen thrombotic (arterial 10, venous 4) and 51 bleeding events (minor 48, major 3) occurred. Sixteen\/150 (10.6%) patients developed secondary myelofibrosis and 3\/150 (2%) an acute myeloid leukaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our experience, anagrelide is an effective drug in reducing platelet levels in a high percentage of patients with ET. It is especially addressed to younger people. A careful assessment of the thrombotic risk and monitoring of cardiac function, at diagnosis and during follow\u2010up, is mandatory.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13454","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T10:01:20Z","timestamp":1590141680000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25\u00a0years by the \u201cPh1\u2010negative Myeloproliferative Neoplasms Latium Group\u201d"],"prefix":"10.1111","volume":"105","author":[{"given":"Maria Gabriella","family":"Mazzucconi","sequence":"first","affiliation":[{"name":"Ematologia Universit\u00e0 Sapienza Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermina","family":"Baldacci","sequence":"additional","affiliation":[{"name":"Ematologia Azienda Ospedaliera Universitaria Policlinico Umberto I Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-862X","authenticated-orcid":false,"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"Ematologia Azienda Ospedaliera Universitaria Policlinico Umberto I Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Ematologia Azienda Ospedaliera Universitaria Policlinico Umberto I Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Paoloni","sequence":"additional","affiliation":[{"name":"Fondazione GIMEMA Franco Mandelli Onlus Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambra","family":"Di Veroli","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Belcolle Viterbo Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cedrone","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale San Giovanni Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Anaclerico","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale San Giovanni Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Villiv\u00e0","sequence":"additional","affiliation":[{"name":"UOSD Ematologia ASL Roma 1 Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Porrini","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Sant'Andrea Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Montefusco","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Sant'Andrea Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Andriani","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Fabrizio Spaziani Frosinone Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Montanaro","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Belcolle Viterbo Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Scaramucci","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Sant'Eugenio Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spadea","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Ematologia e Trapianto di Midollo Osseo Istituto Nazionale Tumori Regina Elena Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2432-235X","authenticated-orcid":false,"given":"Angela","family":"Rago","sequence":"additional","affiliation":[{"name":"UOSD Ematologia ASL Roma 1 Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale Santa Maria Goretti Latina Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Spirito","sequence":"additional","affiliation":[{"name":"Ematologia Ospedale San Camillo Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-447X","authenticated-orcid":false,"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[{"name":"Ematologia Azienda Ospedaliera Universitaria Policlinico Umberto I Roma Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.014"},{"volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001","author":"Jaffe ES","key":"e_1_2_5_3_1"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23585"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23895"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0041-8"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/107602969900500301"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13346"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401270"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.816"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-643346"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08272.x"},{"issue":"2","key":"e_1_2_5_18_1","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.05.022"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339002"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403279"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24293"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-942762"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0792"},{"key":"e_1_2_5_30_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0609.1990.tb00899.x","article-title":"Therapy of essential thrombocythemia with alpha\u2010interferon: results and prospects","volume":"52","author":"Lazzarino M","year":"1990","journal-title":"Eur J Haematol Suppl"},{"issue":"10","key":"e_1_2_5_31_1","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study","volume":"90","author":"Langer C","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30030-3"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"issue":"4","key":"e_1_2_5_35_1","first-page":"315","article-title":"Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results","volume":"77","author":"Mazzucconi MG","year":"1992","journal-title":"Haematologica"},{"issue":"7","key":"e_1_2_5_36_1","first-page":"1136","article-title":"Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany","volume":"12","author":"Petrides PE","year":"1998","journal-title":"Leukemia"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/107602960000600307"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.4.863"},{"issue":"11","key":"e_1_2_5_39_1","first-page":"1306","article-title":"A long\u2010term study of young patients with essential thrombocythemia treated with anagrelide","volume":"89","author":"Mazzucconi MG","year":"2004","journal-title":"Haematologica"},{"issue":"5","key":"e_1_2_5_40_1","first-page":"520","article-title":"Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders","volume":"89","author":"Birgeg\u00e5rd G","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2004.00637.x"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1218-2"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174672"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08122.x"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1"},{"key":"e_1_2_5_48_1","first-page":"177","article-title":"Essential thrombocythaemia: an interim report from the Polycythaemia Vera Study Group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.10.002"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1081"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2017.08.005"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T06:06:04Z","timestamp":1722924364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/ejh.13454"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13454","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"2020-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}